Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ORIG3N, Sharp Edge form drug discovery alliance
As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders. Previously, patients only
As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders. Previously, patients only
First shipments of this new store branded product have been initiated and represents a first-to-market accomplishment for Perrigo and Allergan. These products are packaged and marketed as store
CINQAIR is administered by intravenous (IV) infusion at a weight-based dose of 3 mg/kg once every four weeks. The treatment is expected to become commercially available to patients,
Close to 20 percent of breast cancers are triple-negative, a type of tumor that lacks the three most common receptors that fuel most breast cancer growth. These tumors
The EMA will now initiate its review of the XELJANZ MAA. This application provides additional information to the original MAA submission, including data from the Phase 3 ORAL
The Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with
Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million),
IPF results from the build-up of scar tissue (fibrosis) in the lungs, which prevents normal uptake of oxygen. Scar tissue is comprised of collagen fibres which, when excessively
Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain
Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. "Over the last